-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HmPu0l3I8UkRNJ1pa/fw8KXADsqh7OJ8kNmHm94AN2QJxfVdZbnM9CtkE50mYMZN +Iw6N51czSEPsveWBr5coA== 0001157523-09-000731.txt : 20090202 0001157523-09-000731.hdr.sgml : 20090202 20090202165757 ACCESSION NUMBER: 0001157523-09-000731 CONFORMED SUBMISSION TYPE: 25 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090202 DATE AS OF CHANGE: 20090202 EFFECTIVENESS DATE: 20090202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOPHARM INC CENTRAL INDEX KEY: 0000942788 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 510327886 STATE OF INCORPORATION: DE FISCAL YEAR END: 0907 FILING VALUES: FORM TYPE: 25 SEC ACT: 1934 Act SEC FILE NUMBER: 001-12493 FILM NUMBER: 09562021 BUSINESS ADDRESS: STREET 1: 1850 LAKESIDE DRIVE CITY: WAUKEGAN STATE: IL ZIP: 60085 BUSINESS PHONE: 8472958678 MAIL ADDRESS: STREET 1: C/O WILSON SONSIN GOODRICH & ROSETI STREET 2: 650 PAGE MILL ROAD CITY: PALO ALTO STATE: CA ZIP: 94304 25 1 aa5885997.htm NEOPHARM, INC. FORM 25 aa5885997.htm
 
OMB APPROVAL
OMB Number 3235-0080:
Expires February 28, 2009
Estimated average burden
hours per response…..1.00
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
 
FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-12493     

Issuer:     NeoPharm, Inc.
Exchange:  NASDAQ Capital Market
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)


101 Waukegan Road, Suite 970, Lake Bluff, Illinois 60044                          Telephone:    847/887-0800
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)


Common Stock / $.0002145 (par value)
(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

o    17CFR240.l2d2-2(a)(I)
 
o    17CFR240.12d2-2(a)(2)
 
o    17CFR240.l2d2-2(a)(3)
 
o    17CFR240.12d2-2(a)(4)

 
o   Pursuant to 17 CFR 240. 12d2-2(b ), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1


x   Pursuant to 17 CFR 240 . 12d2- 2( c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240 .12d2- 2( c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.


Pursuant to the requirements of the Securities Exchange Act of 1934, NeoPharm, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.


February 2, 2009
  
By           /s/ Laurence P. Birch
  
President & CEO
Date
  
Name
  
Title


 
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.I9d-1 as applicable. See General Instructions.



SEC 1654(03-06)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
 
 
 -----END PRIVACY-ENHANCED MESSAGE-----